MinervaX
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $126M
Overview
Developing a broad-spectrum vaccine to prevent Group B Streptococcus infections in neonates.
Infectious Disease
Technology Platform
A proprietary platform for designing recombinant fusion protein antigens that provide broad serotype coverage against bacterial pathogens.
Funding History
2Total raised:$126M
Venture$54M
Venture$72M
Opportunities
Addressing a globally significant unmet need with a first-in-class vaccine that could become standard of care in prenatal health.
Risk Factors
Clinical and regulatory risks associated with trials in pregnant women and the need to demonstrate a clear impact on neonatal disease outcomes.
Competitive Landscape
Holds a leading position in GBS vaccinology with limited active competitors, though large pharma could enter the space.